RCS - PureTech Health PLC - PRTC LYT-100 Data & IPF Trial Design at ERS Conf

Puretech HealthAnnouncement

05/09/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220905:nRSE1898Ya&default-theme=true

RNS Number : 1898Y  PureTech Health PLC  05 September 2022

5 September 2022

PureTech Health plc

 

PureTech Presents Data for LYT-100 (Deupirfenidone) Supporting Design of
Dose-Ranging Trial in Idiopathic Pulmonary Fibrosis (IPF) at European
Respiratory Society International Congress 2022

 

LYT-100 was well-tolerated compared to pirfenidone in a healthy older adult
crossover trial, informing dose selection for recently initiated trial in IPF

 

PureTech Health plc (https://puretechhealth.com/) (Nasdaq: PRTC, LSE: PRTC)
("PureTech" or the "Company"), a clinical-stage biotherapeutics company
dedicated to changing the treatment paradigm for devastating diseases, today
announced a poster presentation describing the rationale and design for the
Phase 2 trial of LYT-100 in patients with IPF at the European Respiratory
Society (ERS) International Congress. The poster also reviews the results from
a Phase 1 crossover trial of LYT-100 in healthy older adults, which supports
the dose selection for the Phase 2 trial. LYT-100 is a therapeutic candidate
in PureTech's Wholly Owned Pipeline and is being advanced for the treatment of
conditions involving inflammation and fibrosis, including IPF.

 

The data from the Phase 1 trial demonstrated that LYT-100 showed a lower
incidence of adverse events (AEs) compared to pirfenidone at comparable
exposure levels. Key outcomes of this trial that are supportive of the
observed improved tolerability of LYT-100 were reported
(https://news.puretechhealth.com/news-releases/news-release-details/puretechs-lyt-100-deupirfenidone-achieves-50-reduction-healthy)
 in January 2022. Additionally, this trial supports the dosages that were
selected for the Phase 2 trial of LYT-100, which began in June 2022.

 

"These Phase 1 data provide additional evidence of LYT-100's tolerability
compared to pirfenidone and further support testing a higher dose of LYT-100
in our dose-ranging clinical trial in patients with IPF," said Julie Krop,
M.D., Chief Medical Officer at PureTech. "Pirfenidone's tolerability profile
impacts patient adherence to an otherwise efficacious IPF treatment, resulting
in dose adjustments, discontinuations and ultimately poorer patient outcomes.
We're encouraged by the data we've seen thus far and we look forward to
progressing our Phase 2 trial in patients living with IPF."

 

LYT-100 is a selectively deuterated form of pirfenidone that is designed to
retain the potent and clinically validated anti-fibrotic and anti-inflammatory
activity of pirfenidone with a differentiated pharmacokinetic (PK) profile
that has translated into favorable safety and tolerability, as demonstrated by
data from more than 400 subjects. Pirfenidone is one of the two standard of
care treatments approved for IPF, along with nintedanib, both of which are
efficacious but associated with significant GI-related tolerability issues.
The tolerability issues associated with pirfenidone result in treatment
discontinuations and/or dose reductions below the FDA-approved dose of 801 mg
three times a day (TID), thereby limiting its effectiveness in patients.

 

"For a devastating and progressive disease like IPF, more tolerable and
effective treatment options are critical to curbing premature discontinuation
or sub-optimal dosing," said Toby Maher, M.D., Ph.D., Professor of Medicine
at Keck Medicine of USC Academic Medical Center at the University of
Southern California who is presenting the poster at ERS and is an investigator
in the dose-ranging trial. "The tolerability advantage of LYT-100 over
pirfenidone may enable better patient compliance and potentially lead to
improved outcomes, both for those currently taking standard of care drugs and
- perhaps more importantly - for the approximately 75% of patients with IPF
who are not currently on any approved therapies, often due to tolerability
issues."

 

Phase 1 safety results in healthy older adults

The Phase 1 trial was a double-blind, randomized, two-period crossover trial
of LYT-100 conducted in healthy older adults in the fed state to determine the
safety, tolerability and PK parameters of LYT-100 administered TID for three
days compared to pirfenidone administered TID for three days under fed
conditions. Subjects were randomized to one of two treatment sequences.

 

Results from the Phase 1 trial were announced in January 2022. The expanded
analysis details the safety, tolerability and favorable PK profile of LYT-100
at the 550 mg TID dose in fed healthy volunteers. LYT-100 550 mg TID
administration substantially reduced incidence of GI (50% reduction) and
nervous system (45% reduction) related treatment-emergent adverse events
(TEAEs) compared to pirfenidone in this crossover trial, consistent with a
lower Cmax. The demonstrated tolerability supports testing a higher dose of
LYT-100 in the IPF trial.

 

Dose-ranging trial (ELEVATE) design

The scientific poster also reviews the design of PureTech's dose-ranging trial
of LYT-100 in patients with IPF. The clinical trial's primary objective will
be focused on obtaining clinical data establishing the efficacy, tolerability,
safety and dosing regimen of LYT-100 compared to placebo in order to determine
the dose for a potential Phase 3 trial.  The primary efficacy endpoint is the
rate of decline in Forced Vital Capacity (FVC) over 26 weeks. The secondary
endpoints include change in FVC percentage predicted from baseline to week 26,
time to hospitalization or mortality due to respiratory cause through 26 weeks
and time to IPF progression through 26 weeks, as defined by a decline in FVC
percentage of greater than or equal to five percent. Both doses of LYT-100
will be compared to placebo and pirfenidone with respect to safety and
efficacy during the 26-week trial.

 

The global IPF ELEVATE trial has initiated and is enrolling patients. Visit
clinicaltrial.gov
(https://clinicaltrials.gov/ct2/show/NCT05321420?cond=NCT05321420&draw=2&rank=1)
(NCT05321420) for more details.

 

About Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis is a terminal, orphan condition that is
progressive and characterized by irreversible scarring of the lungs that
worsens over time and makes it difficult to breathe. The prognosis of IPF is
poor, with the median survival after diagnosis generally estimated at two to
five years. Currently available treatment options are associated with
significant tolerability issues and dose-limiting toxicities, which can hamper
treatment compliance and leave patients and physicians needing new treatment
options.

 

About LYT-100

LYT-100 is one of seven therapeutic candidates within PureTech's Wholly Owned
Pipeline. It is a selectively deuterated form of pirfenidone that is designed
to retain the potent and clinically-validated anti-fibrotic and
anti-inflammatory activity of pirfenidone but has a highly differentiated PK
profile that has translated into improved tolerability, as supported by data
from multiple human clinical studies. LYT-100 is being advanced for the
potential treatment of conditions involving inflammation and fibrosis,
including IPF. PureTech is also exploring the potential evaluation of LYT-100
in other inflammatory and fibrotic conditions such as myocardial and other
organ system fibrosis, radiation induced fibrosis, and lymphedema based on the
strength of existing clinical data around the use of pirfenidone in these
indications.

 

About PureTech Health

PureTech is a biotherapeutics company dedicated to changing the treatment
paradigm for devastating diseases. The Company has created a broad and deep
pipeline through the expertise of its experienced research and development
team and its extensive network of scientists, clinicians and industry leaders.
This pipeline, which is being advanced both internally and through PureTech's
Founded Entities, is comprised of 27 therapeutics and therapeutic candidates,
including two that have received both U.S. FDA clearance and European
marketing authorization and a third that will soon be filed for FDA approval,
as of the date of PureTech's most recently filed Half-Year Report and
corresponding Form 6-K. All of the underlying programs and platforms that
resulted in this pipeline of therapeutic candidates were initially identified
or discovered and then advanced by the PureTech team through key validation
points based on unique insights in immunology and drug development.

 

For more information, visit www.puretechhealth.com
(http://www.puretechhealth.com) or connect with us on Twitter @puretechh.

 

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that are or may be forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. All statements contained in this press release that do not relate to
matters of historical fact should be considered forward-looking statements,
including those related to our trial of LYT-100 for the treatment of
idiopathic pulmonary fibrosis, the treatment potential of LYT-100 for patients
with idiopathic pulmonary fibrosis, including its ability to address a
significant unmet need for patients with IPF and certain shortcomings with
respect to current standards of care, expectations regarding the potential of
clinical data to support clinical development of LYT-100 for indications
beyond IPF, our therapeutic candidates and approach towards addressing major
diseases, and our future prospects, developments and strategies. The
forward-looking statements are based on current expectations and are subject
to known and unknown risks, uncertainties and other important factors that
could cause actual results, performance and achievements to differ materially
from current expectations, including, but not limited to, those risks,
uncertainties and other important factors described under the caption "Risk
Factors" in our Annual Report on Form 20-F for the year ended December 31,
2021 filed with the SEC and in our other regulatory filings. These
forward-looking statements are based on assumptions regarding the present and
future business strategies of the Company and the environment in which it will
operate in the future. Each forward-looking statement speaks only as at the
date of this press release. Except as required by law and regulatory
requirements, we disclaim any obligation to update or revise these
forward-looking statements, whether as a result of new information, future
events or otherwise.

 

 Contact:

 PureTech

 Public Relations

 publicrelations@puretechhealth.com (mailto:publicrelations@puretechhealth.com)

 Investor Relations

 IR@puretechhealth.com (mailto:IR@puretechhealth.com)

 EU Media

 Ben Atwell, Rob Winder

 +44 (0) 20 3727 1000

 ben.atwell@FTIconsulting.com (mailto:ben.atwell@FTIconsulting.com)

 U.S. Media

 Nichole Sarkis

 +1 774 278 8273

 nichole@tenbridgecommunications.com
 (mailto:nichole@tenbridgecommunications.com)

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAMZGGLLDGGZZM